Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Standards of Care

3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2021

  1. American Diabetes Association
Diabetes Care 2021 Jan; 44(Supplement 1): S34-S39. https://doi.org/10.2337/dc21-S003
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

For guidelines related to screening for increased risk for type 2 diabetes (prediabetes), please refer to Section 2 “Classification and Diagnosis of Diabetes” (https://doi.org/10.2337/dc21-S002). For guidelines related to screening, diagnosis, and management of type 2 diabetes in youth, please refer to Section 13 “Children and Adolescents” (https://doi.org/10.2337/dc21-S013).

Recommendation

  • 3.1 At least annual monitoring for the development of type 2 diabetes in those with prediabetes is suggested. E

Screening for prediabetes and type 2 diabetes risk through an informal assessment of risk factors (Table 2.3) or with an assessment tool, such as the American Diabetes Association risk test (Fig. 2.1), is recommended to guide providers on whether performing a diagnostic test for prediabetes (Table 2.5) and previously undiagnosed type 2 diabetes (Table 2.2) is appropriate (see Section 2 “Classification and Diagnosis of Diabetes,” https://doi.org/10.2337/dc21-S002). Testing high-risk patients for prediabetes is warranted because the laboratory assessment is safe and reasonable in cost, substantial time exists before the development of type 2 diabetes and its complications during which one can intervene, and there is an effective means of preventing type 2 diabetes in those determined to have prediabetes with an A1C 5.7–6.4% (39–47 mmol/mol), impaired glucose tolerance, or impaired fasting glucose. Using A1C to screen for prediabetes may be problematic in the presence of certain hemoglobinopathies or conditions that affect red blood cell turnover. See Section 2 “Classification and Diagnosis of Diabetes” (https://doi.org/10.2337/dc21-S002) and Section 6 “Glycemic Targets” (https://care.diabetesjournals.org/lookup/doi/10.2337/dc21-S006) for additional details on the appropriate use of the A1C test.

Lifestyle Behavior Change for Diabetes Prevention

Recommendations

  • 3.2 Refer patients with prediabetes to an intensive lifestyle behavior change program modeled on the Diabetes Prevention Program to achieve and maintain 7% loss of initial body weight and increase moderate-intensity physical activity (such as brisk walking) to at least 150 min/week. A

  • 3.3 A variety of eating patterns can be considered to prevent diabetes in individuals with prediabetes. B

  • 3.4 Based on patient preference, certified technology-assisted diabetes prevention programs may be effective in preventing type 2 diabetes and should be considered. B

  • 3.5 Given the cost-effectiveness of lifestyle behavior modification programs for diabetes prevention A, such diabetes prevention programs should be covered by third-party payers.

The Diabetes Prevention Program

Several major randomized controlled trials, including the Diabetes Prevention Program (DPP) (1), the Finnish Diabetes Prevention Study (DPS) (2), and the Da Qing Diabetes Prevention Study (Da Qing study) (3), demonstrate that lifestyle/behavioral therapy featuring an individualized reduced-calorie meal plan is highly effective in preventing type 2 diabetes and improving other cardiometabolic markers (such as blood pressure, lipids, and inflammation) (4). The strongest evidence for diabetes prevention in the U.S. comes from the DPP trial (1). The DPP demonstrated that an intensive lifestyle intervention could reduce the risk of incident type 2 diabetes by 58% over 3 years. Follow-up of three large studies of lifestyle intervention for diabetes prevention has shown sustained reduction in the risk of conversion to type 2 diabetes: 39% reduction at 30 years in the Da Qing study (5), 43% reduction at 7 years in the Finnish DPS (2), and 34% reduction at 10 years (6) and 27% reduction at 15 years (7) in the U.S. Diabetes Prevention Program Outcomes Study (DPPOS).

The two major goals of the DPP intensive lifestyle intervention were to achieve and maintain a minimum of 7% weight loss and 150 min of physical activity per week similar in intensity to brisk walking. The DPP lifestyle intervention was a goal-based intervention: all participants were given the same weight loss and physical activity goals, but individualization was permitted in the specific methods used to achieve the goals (8). Although weight loss was the most important factor to reduce the risk of incident diabetes, it was also found that achieving the target behavioral goal of at least 150 min of physical activity per week, even without weight loss, reduced the incidence of type 2 diabetes by 44% (9).

The 7% weight loss goal was selected because it was feasible to achieve and maintain and likely to lessen the risk of developing diabetes. Participants were encouraged to achieve the 7% weight loss during the first 6 months of the intervention. However, longer-term (4-year) data reveal maximal prevention of diabetes observed at about 7–10% weight loss (9). The recommended pace of weight loss was 1–2 lb/week. Calorie goals were calculated by estimating the daily calories needed to maintain the participant's initial weight and subtracting 500–1,000 calories/day (depending on initial body weight). The initial focus was on reducing total dietary fat. After several weeks, the concept of calorie balance and the need to restrict calories as well as fat was introduced (8).

The goal for physical activity was selected to approximate at least 700 kcal/week expenditure from physical activity. For ease of translation, this goal was described as at least 150 min of moderate-intensity physical activity per week similar in intensity to brisk walking. Participants were encouraged to distribute their activity throughout the week with a minimum frequency of three times per week and at least 10 min per session. A maximum of 75 min of strength training could be applied toward the total 150 min/week physical activity goal (8).

To implement the weight loss and physical activity goals, the DPP used an individual model of treatment rather than a group-based approach. This choice was based on a desire to intervene before participants had the possibility of developing diabetes or losing interest in the program. The individual approach also allowed for tailoring of interventions to reflect the diversity of the population (8).

The DPP intervention was administered as a structured core curriculum followed by a more flexible maintenance program of individual sessions, group classes, motivational campaigns, and restart opportunities. The 16-session core curriculum was completed within the first 24 weeks of the program and included sections on lowering calories, increasing physical activity, self-monitoring, maintaining healthy lifestyle behaviors, and psychological, social, and motivational challenges. Further details are available regarding the core curriculum sessions (8).

Nutrition

The dietary counseling for weight loss in the DPP intervention included a reduction of total dietary fat and calories to prevent diabetes for those at high risk for developing type 2 diabetes with an overweight or obese BMI (1,8,9). However, evidence suggests that there is not an ideal percentage of calories from carbohydrate, protein, and fat for all people to prevent diabetes; therefore, macronutrient distribution should be based on an individualized assessment of current eating patterns, preferences, and metabolic goals (10). Based on other intervention trials, a variety of eating patterns characterized by the totality of food and beverages consumed (10,11) may also be appropriate for patients with prediabetes (10), including Mediterranean-style and low-carbohydrate eating plans (12–15). Observational studies have also shown that vegetarian, plant-based (may include some animal products), and Dietary Approaches to Stop Hypertension (DASH) eating patterns are associated with a lower risk of developing type 2 diabetes (16–19). Evidence suggests that the overall quality of food consumed (as measured by the Healthy Eating Index, Alternative Healthy Eating Index, and DASH score), with an emphasis on whole grains, legumes, nuts, fruits, and vegetables and minimal refined and processed foods, is also associated with a lower risk of type 2 diabetes (18,20–23). As is the case for those with diabetes, individualized medical nutrition therapy (see Section 5 “Facilitating Behavior Change and Well-being to Improve Health Outcomes,” https://doi.org/10.2337/dc21-S005, for more detailed information) is effective in lowering A1C in individuals diagnosed with prediabetes (24).

Physical Activity

Just as 150 min/week of moderate-intensity physical activity, such as brisk walking, showed beneficial effects in those with prediabetes (1), moderate-intensity physical activity has been shown to improve insulin sensitivity and reduce abdominal fat in children and young adults (25,26). On the basis of these findings, providers are encouraged to promote a DPP-style program, including a focus on physical activity, to all individuals who have been identified to be at an increased risk of type 2 diabetes. In addition to aerobic activity, an exercise regimen designed to prevent diabetes may include resistance training (8,27,28). Breaking up prolonged sedentary time may also be encouraged, as it is associated with moderately lower postprandial glucose levels (29,30). The preventive effects of exercise appear to extend to the prevention of gestational diabetes mellitus (GDM) (31).

Delivery and Dissemination of Lifestyle Behavior Change for Diabetes Prevention

Because the intensive lifestyle intervention in the DPP was effective in preventing type 2 diabetes for those at high risk for the disease and lifestyle behavior change programs for diabetes prevention were shown to be cost-effective, broader efforts to disseminate scalable lifestyle behavior change programs for diabetes prevention with coverage by third-party payers ensued (32–36). Group delivery of DPP content in community or primary care settings has demonstrated the potential to reduce overall program costs while still producing weight loss and diabetes risk reduction (37–41).

The Centers for Disease Control and Prevention (CDC) developed the National Diabetes Prevention Program (National DPP), a resource designed to bring such evidence-based lifestyle change programs for preventing type 2 diabetes to communities (www.cdc.gov/diabetes/prevention/index.htm). This online resource includes locations of CDC-recognized diabetes prevention lifestyle change programs (available at https://nccd.cdc.gov/DDT_DPRP/Programs.aspx). To be eligible for this program, patients must have a BMI in the overweight range and be at risk for diabetes based on laboratory testing or a positive risk test (available at www.cdc.gov/prediabetes/takethetest/). Results from the CDC's National DPP during the first 4 years of implementation are promising and demonstrate cost-efficacy (42). The CDC has also developed the Diabetes Prevention Impact Tool Kit (available at https://nccd.cdc.gov/toolkit/diabetesimpact) to help organizations assess the economics of providing or covering the National DPP lifestyle change program (43). In an effort to expand preventive services using a cost-effective model that began in April 2018, the Centers for Medicare & Medicaid Services expanded Medicare reimbursement coverage for the National DPP lifestyle intervention to organizations recognized by the CDC that become Medicare suppliers for this service (online at https://innovation.cms.gov/innovation-models/medicare-diabetes-prevention-program). The locations of Medicare DPPs are available online at https://innovation.cms.gov/innovation-models/medicare-diabetes-prevention-program/mdpp-map. To qualify for Medicare coverage, patients must have a BMI in the overweight range and laboratory testing consistent with prediabetes in the last year. Medicaid coverage of the DPP lifestyle intervention is also expanding on a state-by-state basis.

While CDC-recognized lifestyle change programs and Medicare DPP services have the advantages of having met minimum quality standards and being reimbursed by various payers, there have been lower retention rates in such programs reported for younger adults and racial/ethnic minority populations (44). Therefore, other programs and modalities of lifestyle behavior changes for achieving the goals for diabetes prevention may also be appropriate and efficacious based on patient preferences and availability. The use of community health workers to support DPP efforts has been shown to be effective with cost savings (45,46) (see Section 1 “Improving Care and Promoting Health in Populations,” https://doi.org/10.2337/dc21-S001, for more information). The use of community health workers may facilitate adoption of lifestyle behavior changes for diabetes prevention while bridging barriers related to social determinants of health, though coverage by third-party payers sometimes remains problematic. Registered dietitian nutritionists (RDN) can help individuals with prediabetes reach their goals of improving eating habits, increasing moderate-intensity physical activity, and achieving 7–10% loss of initial body weight (10,47–49). Individualized medical nutrition therapy (see Section 5 “Facilitating Behavior Change and Well-being to Improve Health Outcomes,” https://doi.org/10.2337/dc21-S005, for more detailed information) is also effective in improving glycemia in individuals diagnosed with prediabetes (24,47). Furthermore, these trials involving medical nutrition therapy for patients with prediabetes found significant reductions in weight, waist circumference, and glycemia. Individuals with prediabetes can benefit from being referred to an RDN for individualized medical nutrition therapy upon diagnosis and at regular intervals throughout their treatment regimen (49,50). Other allied health professionals, like pharmacists and diabetes care and education specialists, also have the capability of delivering lifestyle behavior change programs and may be considered for diabetes prevention efforts (51,52).

Technology-assisted programs may effectively deliver the DPP lifestyle program, reducing weight and, therefore, diabetes risk (53–58). Such technology-assisted programs may deliver content through smartphone, web-based applications, and telehealth, and may be an acceptable and efficacious option to bridge barriers particularly for low-income and rural patients; however, not all programs are effective in helping people reach targets for diabetes prevention (53,59–61). The CDC Diabetes Prevention Recognition Program (DPRP) (www.cdc.gov/diabetes/prevention/requirements-recognition.htm) certifies technology-assisted modalities as effective vehicles for DPP-based programs; such programs must use an approved curriculum, include interaction with a coach, and attain the DPRP outcomes of participation, physical activity reporting, and weight loss. Therefore, providers should consider referring patients with prediabetes to certified technology–assisted DPP programs based on patient preference.

Pharmacologic Interventions

Recommendations

  • 3.6 Metformin therapy for prevention of type 2 diabetes should be considered in those with prediabetes, especially for those with BMI ≥35 kg/m2, those aged <60 years, and women with prior gestational diabetes mellitus. A

  • 3.7 Long-term use of metformin may be associated with biochemical vitamin B12 deficiency; consider periodic measurement of vitamin B12 levels in metformin-treated patients, especially in those with anemia or peripheral neuropathy. B

Because weight loss through behavior changes in diet and exercise alone can be difficult to maintain long term (6), people being treated with weight loss therapy may benefit from support and additional pharmacotherapeutic options, if needed. Various pharmacologic agents used to treat diabetes have been evaluated for diabetes prevention. Metformin, α-glucosidase inhibitors, liraglutide, thiazolidinediones, and insulin have been shown to lower the risk of diabetes in those with prediabetes (62–67); whereas diabetes prevention was not seen with nateglinide (68). In addition, several weight loss medications like orlistat and phenteramine-topiramate have also been shown in research studies to decrease the incidence of diabetes to various degrees in those with prediabetes (69,70). Studies of other pharmacologic agents have shown some efficacy in diabetes prevention with valsartan but no efficacy with ramipril, anti-inflammatory drugs, or vitamin D in preventing diabetes (71–75). However, no pharmacologic agent has been approved by the U.S. Food and Drug Administration specifically for diabetes prevention. The risk versus benefit of each medication must be weighed. Metformin has the strongest evidence base (1) and demonstrated long-term safety as pharmacologic therapy for diabetes prevention (76). For other drugs, cost, side effects, and durable efficacy require consideration.

Metformin was overall less effective than lifestyle modification in the DPP, though group differences declined over time in the DPPOS (7), and metformin may be cost-saving over a 10-year period (34). During initial follow-up in the DPP, metformin was as effective as lifestyle modification in participants with BMI ≥35 kg/m2 and in younger participants aged 25–44 years (1). In the DPP, for women with a history of GDM, metformin and intensive lifestyle modification led to an equivalent 50% reduction in diabetes risk (77), and both interventions remained highly effective during a 10-year follow-up period (78). By the time of the 15-year follow-up (DPPOS), exploratory analyses demonstrated that participants with a higher baseline fasting glucose (≥110 mg/dL vs. 95–109 mg/dL) and women with a history of GDM (vs. women without a history of GDM) experienced higher risk reductions with metformin (compared with the placebo arm) (79). In the Indian Diabetes Prevention Programme (IDPP-1), metformin and the lifestyle intervention reduced diabetes risk similarly at 30 months; of note, the lifestyle intervention in IDPP-1 was less intensive than that in the DPP (80). Based on findings from the DPP, metformin should be recommended as an option for high-risk individuals (e.g., those with a history of GDM or those with BMI ≥35 kg/m2). Consider monitoring vitamin B12 levels in those taking metformin chronically to check for possible deficiency (81,82) (see Section 9 “Pharmacologic Approaches to Glycemic Treatment,” https://doi.org/10.2337/dc21-S009, for more details).

Prevention of Vascular Disease and Mortality

Recommendation

  • 3.8 Prediabetes is associated with heightened cardiovascular risk; therefore, screening for and treatment of modifiable risk factors for cardiovascular disease are suggested. B

People with prediabetes often have other cardiovascular risk factors, including hypertension and dyslipidemia (83), and are at increased risk for cardiovascular disease (84,85). Evaluation for tobacco use and referral for tobacco cessation, if indicated, should be part of routine care for those at risk for diabetes. Of note, the years immediately following smoking cessation may represent a time of increased risk for diabetes (86–88), a time when patients should be monitored for diabetes development and receive the concurrent evidence-based lifestyle behavior change for diabetes prevention described in this section. See Section 5 “Facilitating Behavior Change and Well-being to Improve Health Outcomes” (https://doi.org/10.2337/dc21-S005) for more detailed information. The lifestyle interventions for weight loss in study populations at risk for type 2 diabetes have shown a reduction in cardiovascular risk factors and the need for medications used to treat these cardiovascular risk factors (89,90). In longer-term follow-up, lifestyle interventions for diabetes prevention also prevented the development of microvascular complications among women enrolled in the DPPOS and in the study population enrolled in the China Da Qing Diabetes Prevention Outcome Study (7,91). The lifestyle intervention in the latter study was also efficacious in preventing cardiovascular disease and mortality at 23 and 30 years of follow-up (3,5). Treatment goals and therapies for hypertension and dyslipidemia in the primary prevention of cardiovascular disease for people with prediabetes should be based on their level of cardiovascular risk, and increased vigilance is warranted to identify and treat these and other cardiovascular risk factors (92).

Footnotes

  • Suggested citation: American Diabetes Association. 3. Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021;44(Suppl. 1):S34–S39

  • © 2020 by the American Diabetes Association
https://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Knowler WC,
    2. Barrett-Connor E,
    3. Fowler SE, et al.; Diabetes Prevention Program Research Group
    . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Lindström J,
    2. Ilanne-Parikka P,
    3. Peltonen M, et al.; Finnish Diabetes Prevention Study Group
    . Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673–1679
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Li G,
    2. Zhang P,
    3. Wang J, et al
    . Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014;2:474–480
    OpenUrl
  4. ↵
    1. Nathan DM,
    2. Bennett PH,
    3. Crandall JP, et al.; Research Group
    . Does diabetes prevention translate into reduced long-term vascular complications of diabetes? Diabetologia 2019;62:1319–1328
    OpenUrl
  5. ↵
    1. Gong Q,
    2. Zhang P,
    3. Wang J, et al.; Da Qing Diabetes Prevention Study Group
    . Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol 2019;7:452–461
    OpenUrl
  6. ↵
    1. Knowler WC,
    2. Fowler SE,
    3. Hamman RF, et al.; Diabetes Prevention Program Research Group
    . 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677–1686
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Nathan DM,
    2. Barrett-Connor E,
    3. Crandall JP, et al
    . Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications: the DPP Outcomes Study. Lancet Diabetes Endocrinol 2015;3:866–875
    OpenUrlPubMed
  8. ↵
    1. Diabetes Prevention Program (DPP) Research Group
    . The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002;25:2165–2171
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hamman RF,
    2. Wing RR,
    3. Edelstein SL, et al
    . Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006;29:2102–2107
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Evert AB,
    2. Dennison M,
    3. Gardner CD, et al
    . Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 2019;42:731–754
    OpenUrlFREE Full Text
  11. ↵
    Department of Health and Human Services and Department of Agriculture. Dietary Guidelines for Americans 2015–2020, Eighth Edition. Accessed 5 October 2020. Available from https://health.gov/dietaryguidelines/2015/guidelines
  12. ↵
    1. Salas-Salvadó J,
    2. Guasch-Ferré M,
    3. Lee C-H,
    4. Estruch R,
    5. Clish CB,
    6. Ros E
    . Protective effects of the Mediterranean diet on type 2 diabetes and metabolic syndrome. J Nutr 2016;146:920S–927S
    1. Bloomfield HE,
    2. Koeller E,
    3. Greer N,
    4. MacDonald R,
    5. Kane R,
    6. Wilt TJ
    . Effects on health outcomes of a Mediterranean diet with no restriction on fat intake: a systematic review and meta-analysis. Ann Intern Med 2016;165:491–500
    OpenUrlCrossRefPubMed
    1. Estruch R,
    2. Ros E,
    3. Salas-Salvadó J,
    4. Covas M-I,
    5. Corella D,
    6. Arós F, et al
    . Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018;21:e34
    OpenUrl
  13. ↵
    1. Stentz FB,
    2. Brewer A,
    3. Wan J, et al
    . Remission of pre-diabetes to normal glucose tolerance in obese adults with high protein versus high carbohydrate diet: randomized control trial. BMJ Open Diabetes Res Care 2016;4:e000258
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Chiu THT,
    2. Pan W-H,
    3. Lin M-N,
    4. Lin C-L
    . Vegetarian diet, change in dietary patterns, and diabetes risk: a prospective study. Nutr Diabetes 2018;8:12
    OpenUrlPubMed
    1. Lee Y,
    2. Park K
    . Adherence to a vegetarian diet and diabetes risk: a systematic review and meta-analysis of observational studies. Nutrients 2017;9:E603
    OpenUrlCrossRefPubMed
  15. ↵
    1. Qian F,
    2. Liu G,
    3. Hu FB,
    4. Bhupathiraju SN,
    5. Sun Q
    . Association between plant-based dietary patterns and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA Intern Med 2019;179:1335–1344
    OpenUrl
  16. ↵
    1. Esposito K,
    2. Chiodini P,
    3. Maiorino MI,
    4. Bellastella G,
    5. Panagiotakos D,
    6. Giugliano D
    . Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies. Endocrine 2014;47:107–116
    OpenUrlCrossRefPubMed
  17. ↵
    1. Ley SH,
    2. Hamdy O,
    3. Mohan V,
    4. Hu FB
    . Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet 2014;383:1999–2007
    OpenUrlCrossRefPubMedWeb of Science
    1. Jacobs S,
    2. Harmon BE,
    3. Boushey CJ, et al
    . A priori-defined diet quality indexes and risk of type 2 diabetes: the Multiethnic Cohort. Diabetologia 2015;58:98–112
    OpenUrlCrossRefPubMed
    1. Chiuve SE,
    2. Fung TT,
    3. Rimm EB, et al
    . Alternative dietary indices both strongly predict risk of chronic disease. J Nutr 2012;142:1009–1018
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Schwingshackl L,
    2. Bogensberger B,
    3. Hoffmann G
    . Diet quality as assessed by the Healthy Eating Index, Alternate Healthy Eating Index, Dietary Approaches to Stop Hypertension score, and Health Outcomes: an updated systematic review and meta-analysis of cohort studies. J Acad Nutr Diet 2018;118:74–100.e11
    OpenUrlCrossRefPubMed
  19. ↵
    1. Parker AR,
    2. Byham-Gray L,
    3. Denmark R,
    4. Winkle PJ
    . The effect of medical nutrition therapy by a registered dietitian nutritionist in patients with prediabetes participating in a randomized controlled clinical research trial. J Acad Nutr Diet 2014;114:1739–1748
    OpenUrlCrossRefPubMed
  20. ↵
    1. Fedewa MV,
    2. Gist NH,
    3. Evans EM,
    4. Dishman RK
    . Exercise and insulin resistance in youth: a meta-analysis. Pediatrics 2014;133:e163–e174
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Davis CL,
    2. Pollock NK,
    3. Waller JL, et al
    . Exercise dose and diabetes risk in overweight and obese children: a randomized controlled trial. JAMA 2012;308:1103–1112
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Sigal RJ,
    2. Alberga AS,
    3. Goldfield GS, et al
    . Effects of aerobic training, resistance training, or both on percentage body fat and cardiometabolic risk markers in obese adolescents: the healthy eating aerobic and resistance training in youth randomized clinical trial. JAMA Pediatr 2014;168:1006–1014
    OpenUrl
  23. ↵
    1. Dai X,
    2. Zhai L,
    3. Chen Q, et al
    . Two-year-supervised resistance training prevented diabetes incidence in people with prediabetes: a randomised control trial. Diabetes Metab Res Rev 2019;35:e3143
    OpenUrl
  24. ↵
    1. Thorp AA,
    2. Kingwell BA,
    3. Sethi P,
    4. Hammond L,
    5. Owen N,
    6. Dunstan DW
    . Alternating bouts of sitting and standing attenuate postprandial glucose responses. Med Sci Sports Exerc 2014;46:2053–2061
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Healy GN,
    2. Dunstan DW,
    3. Salmon J, et al
    . Breaks in sedentary time: beneficial associations with metabolic risk. Diabetes Care 2008;31:661–666
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Russo LM,
    2. Nobles C,
    3. Ertel KA,
    4. Chasan-Taber L,
    5. Whitcomb BW
    . Physical activity interventions in pregnancy and risk of gestational diabetes mellitus: a systematic review and meta-analysis. Obstet Gynecol 2015;125:576–582
    OpenUrlCrossRefPubMed
  27. ↵
    1. Herman WH,
    2. Hoerger TJ,
    3. Brandle M, et al.; Diabetes Prevention Program Research Group
    . The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323–332
    OpenUrlCrossRefPubMedWeb of Science
    1. Chen F,
    2. Su W,
    3. Becker SH, et al
    . Clinical and economic impact of a digital, remotely-delivered intensive behavioral counseling program on Medicare beneficiaries at risk for diabetes and cardiovascular disease. PLoS One 2016;11:e0163627
    OpenUrlCrossRefPubMed
  28. ↵
    1. Diabetes Prevention Program Research Group
    . The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012;35:723–730
    OpenUrlAbstract/FREE Full Text
    1. Alva ML,
    2. Hoerger TJ,
    3. Jeyaraman R,
    4. Amico P,
    5. Rojas-Smith L
    . Impact of the YMCA of the USA Diabetes Prevention Program on Medicare spending and utilization. Health Aff (Millwood) 2017;36:417–424
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Zhou X,
    2. Siegel KR,
    3. Ng BP, et al
    . Cost-effectiveness of diabetes prevention interventions targeting high-risk individuals and whole populations: a systematic review. Diabetes Care 2020;43:1593–1616
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Ackermann RT,
    2. Finch EA,
    3. Brizendine E,
    4. Zhou H,
    5. Marrero DG
    . Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med 2008;35:357–363
    OpenUrlCrossRefPubMedWeb of Science
    1. Balk EM,
    2. Earley A,
    3. Raman G,
    4. Avendano EA,
    5. Pittas AG,
    6. Remington PL
    . Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann Intern Med 2015;163:437–451
    1. Li R,
    2. Qu S,
    3. Zhang P, et al
    . Economic evaluation of combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann Intern Med 2015;163:452–460
    OpenUrlCrossRefPubMed
    1. Gilmer T,
    2. O’Connor PJ,
    3. Schiff JS, et al
    . Cost-effectiveness of a community-based Diabetes Prevention Program with participation incentives for Medicaid beneficiaries. Health Serv Res 2018;53:4704–4724
    OpenUrlPubMed
  31. ↵
    1. Ackermann RT,
    2. Kang R,
    3. Cooper AJ, et al
    . Effect on health care expenditures during nationwide implementation of the Diabetes Prevention Program as a health insurance benefit. Diabetes Care 2019;42:1776–1783
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Ely EK,
    2. Gruss SM,
    3. Luman ET, et al
    . A national effort to prevent type 2 diabetes: participant-level evaluation of CDC’s National Diabetes Prevention Program. Diabetes Care 2017;40:1331–1341
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Lanza A,
    2. Soler R,
    3. Smith B,
    4. Hoerger T,
    5. Neuwahl S,
    6. Zhang P
    . The Diabetes Prevention Impact Tool Kit: an online tool kit to assess the cost-effectiveness of preventing type 2 diabetes. J Public Health Manag Pract 2019;25:E1–E5
    OpenUrl
  34. ↵
    1. Cannon MJ,
    2. Masalovich S,
    3. Ng BP, et al
    . Retention among participants in the National Diabetes Prevention Program lifestyle change program, 2012–2017. Diabetes Care 2020;43:2042–2049
    OpenUrlAbstract/FREE Full Text
  35. ↵
    The Community Guide. Diabetes prevention: interventions engaging community health workers, 2016. Accessed 5 October 2020. Available from https://www.thecommunityguide.org/findings/diabetes-prevention-interventions-engaging-community-health-workers
  36. ↵
    1. Jacob V,
    2. Chattopadhyay SK,
    3. Hopkins DP, et al
    . Economics of community health workers for chronic disease: findings from community guide systematic reviews. Am J Prev Med 2019;56:e95–e106
    OpenUrl
  37. ↵
    1. Raynor HA,
    2. Davidson PG,
    3. Burns H, et al
    . Medical nutrition therapy and weight loss questions for the Evidence Analysis Library prevention of type 2 diabetes project: systematic reviews. J Acad Nutr Diet 2017;117:1578–1611
    OpenUrlPubMed
    1. Sun Y,
    2. You W,
    3. Almeida F,
    4. Estabrooks P,
    5. Davy B
    . The effectiveness and cost of lifestyle interventions including nutrition education for diabetes prevention: a systematic review and meta-analysis. J Acad Nutr Diet 2017;117:404–421.e36
    OpenUrlCrossRefPubMed
  38. ↵
    1. Briggs Early K,
    2. Stanley K
    . Position of the Academy of Nutrition and Dietetics: the role of medical nutrition therapy and registered dietitian nutritionists in the prevention and treatment of prediabetes and type 2 diabetes. J Acad Nutr Diet 2018;118:343–353
    OpenUrlCrossRefPubMed
  39. ↵
    1. Powers MA,
    2. Bardsley JK,
    3. Cypress M, et al
    . Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care 2020;43:1636–1649
    OpenUrlFREE Full Text
  40. ↵
    1. Hudspeth BD
    . Power of prevention: the pharmacist’s role in prediabetes management. Diabetes Spectr 2018;31:320–323
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Butcher MK,
    2. Vanderwood KK,
    3. Hall TO,
    4. Gohdes D,
    5. Helgerson SD,
    6. Harwell TS
    . Capacity of diabetes education programs to provide both diabetes self-management education and to implement diabetes prevention services. J Public Health Manag Pract 2011;17:242–247
    OpenUrlCrossRefPubMed
  42. ↵
    1. Grock S,
    2. Ku J-H,
    3. Kim J,
    4. Moin T
    . A review of technology-assisted interventions for diabetes prevention. Curr Diab Rep 2017;17:107
    OpenUrl
    1. Sepah SC,
    2. Jiang L,
    3. Peters AL
    . Translating the Diabetes Prevention Program into an online social network: validation against CDC standards. Diabetes Educ 2014;40:435–443
    OpenUrlCrossRefPubMed
    1. Bian RR,
    2. Piatt GA,
    3. Sen A, et al
    . The effect of technology-mediated diabetes prevention interventions on weight: a meta-analysis. J Med Internet Res 2017;19:e76
    OpenUrlPubMed
    1. Sepah SC,
    2. Jiang L,
    3. Peters AL
    . Long-term outcomes of a Web-based diabetes prevention program: 2-year results of a single-arm longitudinal study. J Med Internet Res 2015;17:e92
    OpenUrlCrossRefPubMed
    1. Moin T,
    2. Damschroder LJ,
    3. AuYoung M, et al
    . Results from a trial of an online diabetes prevention program intervention. Am J Prev Med 2018;55:583–591
    OpenUrl
  43. ↵
    1. Michaelides A,
    2. Major J,
    3. Pienkosz E Jr,
    4. Wood M,
    5. Kim Y,
    6. Toro-Ramos T
    . Usefulness of a novel mobile diabetes prevention program delivery platform with human coaching: 65-week observational follow-up. JMIR Mhealth Uhealth 2018;6:e93
    OpenUrl
  44. ↵
    1. Kim SE,
    2. Castro Sweet CM,
    3. Cho E,
    4. Tsai J,
    5. Cousineau MR
    . Evaluation of a digital diabetes prevention program adapted for low-income patients, 2016-2018. Prev Chronic Dis 2019;27:E155
    OpenUrl
    1. Vadheim LM,
    2. Patch K,
    3. Brokaw SM, et al
    . Telehealth delivery of the diabetes prevention program to rural communities. Transl Behav Med 2017;7:286–291
    OpenUrlPubMed
  45. ↵
    1. Fischer HH,
    2. Durfee MJ,
    3. Raghunath SG,
    4. Ritchie ND
    . Short message service text message support for weight loss in patients with prediabetes: pragmatic trial. JMIR Diabetes 2019;4:e12985
    OpenUrl
  46. ↵
    1. Chiasson J-L,
    2. Josse RG,
    3. Gomis R,
    4. Hanefeld M,
    5. Karasik A,
    6. Laakso M; STOP-NIDDM Trail Research Group
    . Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072–2077
    OpenUrlCrossRefPubMedWeb of Science
    1. le Roux CW,
    2. Astrup A,
    3. Fujioka K, et al.; SCALE Obesity Prediabetes NN8022-1839 Study Group
    . 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017;389:1399–1409
    OpenUrlCrossRefPubMed
    1. Gerstein HC,
    2. Yusuf S,
    3. Bosch J, et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
    . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–1105
    OpenUrlCrossRefPubMedWeb of Science
    1. DeFronzo RA,
    2. Tripathy D,
    3. Schwenke DC, et al.; ACT NOW Study
    . Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104–1115
    OpenUrlCrossRefPubMedWeb of Science
    1. Kawamori R,
    2. Tajima N,
    3. Iwamoto Y,
    4. Kashiwagi A,
    5. Shimamoto K,
    6. Kaku K; Voglibose Ph-3 Study Group
    . Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607–1614
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    1. Gerstein HC,
    2. Bosch J,
    3. Dagenais GR, et al.; ORIGIN Trial Investigators
    . Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–328
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Holman RR,
    2. Haffner SM,
    3. McMurray JJ, et al.; NAVIGATOR Study Group
    . Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463–1476
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Torgerson JS,
    2. Hauptman J,
    3. Boldrin MN,
    4. Sjöström L
    . XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–161
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Garvey WT,
    2. Ryan DH,
    3. Henry R, et al
    . Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care 2014;37:912–921
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. McMurray JJ,
    2. Holman RR,
    3. Haffner SM, et al.; NAVIGATOR Study Group
    . Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477–1490
    OpenUrlCrossRefPubMedWeb of Science
    1. Bosch J,
    2. Yusuf S,
    3. Gerstein HC, et al.; DREAM Trial Investigators
    . Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551–1562
    OpenUrlCrossRefPubMedWeb of Science
    1. Everett BM,
    2. Donath MY,
    3. Pradhan AD,
    4. Thuren T,
    5. Pais P,
    6. Nicolau JC, et al
    . Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol 2018;29:2392–2401
    OpenUrl
    1. Pittas AG,
    2. Dawson-Hughes B,
    3. Sheehan P, et al.; D2d Research Group
    . Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med 2019;381:520–530
    OpenUrlCrossRefPubMed
  52. ↵
    1. Ray KK,
    2. Colhoun HM,
    3. Szarek M, et al.; ODYSSEY OUTCOMES Committees and Investigators
    . Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:618–628
    OpenUrl
  53. ↵
    1. Diabetes Prevention Program Research Group
    . Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012;35:731–737
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Ratner RE,
    2. Christophi CA,
    3. Metzger BE, et al.; Diabetes Prevention Program Research Group
    . Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008;93:4774–4779
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    1. Aroda VR,
    2. Christophi CA,
    3. Edelstein SL, et al.; Diabetes Prevention Program Research Group
    . The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program Outcomes Study 10-year follow-up. J Clin Endocrinol Metab 2015;100:1646–1653
    OpenUrlCrossRefPubMed
  56. ↵
    1. Diabetes Prevention Program Research Group
    . Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 2019;42:601–608
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Ramachandran A,
    2. Snehalatha C,
    3. Mary S,
    4. Mukesh B,
    5. Bhaskar AD,
    6. Vijay V; Indian Diabetes Prevention Programme (IDPP)
    . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289–297
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    1. Griffin SJ,
    2. Bethel MA,
    3. Holman RR, et al
    . Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technol Assess 2018;22:1–64
    OpenUrlCrossRefPubMed
  59. ↵
    1. Aroda VR,
    2. Edelstein SL,
    3. Goldberg RB, et al.; Diabetes Prevention Program Research Group
    . Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016;101:1754–1761
    OpenUrlCrossRefPubMed
  60. ↵
    1. Ali MK,
    2. Bullard KM,
    3. Saydah S,
    4. Imperatore G,
    5. Gregg EW
    . Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014. Lancet Diabetes Endocrinol 2018;6:392–403
    OpenUrl
  61. ↵
    1. Pan Y,
    2. Chen W,
    3. Wang Y
    . Prediabetes and outcome of ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2019;28:683–692
    OpenUrl
  62. ↵
    1. Huang Y,
    2. Cai X,
    3. Mai W,
    4. Li M,
    5. Hu Y
    . Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016;355:i5953
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Yeh H-C,
    2. Duncan BB,
    3. Schmidt MI,
    4. Wang N-Y,
    5. Brancati FL
    . Smoking, smoking cessation, and risk for type 2 diabetes mellitus: a cohort study. Ann Intern Med 2010;152:10–17
    OpenUrlCrossRefPubMedWeb of Science
    1. Oba S,
    2. Noda M,
    3. Waki K, et al
    .; Japan Public Health Center-based Prospective Study Group. Smoking cessation increases short-term risk of type 2 diabetes irrespective of weight gain: the Japan Public Health Center-Based Prospective Study [published correction appears in PLoS One 2013;8:10.1371/annotation/23aa7c42-9a4d-42a7-8f50-9d0ac4b85396]. PLoS One 2012;7:e17061
    OpenUrlPubMed
  64. ↵
    1. Hu Y,
    2. Zong G,
    3. Liu G,
    4. Wang M,
    5. Rosner B,
    6. Pan A, et al
    . Smoking cessation, weight change, type 2 diabetes, and mortality. N Engl J Med. 2018 16;379:623–632
    OpenUrl
  65. ↵
    1. Orchard TJ,
    2. Temprosa M,
    3. Barrett-Connor E, et al.; Diabetes Prevention Program Outcomes Study Research Group
    . Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med 2013;30:46–55
    OpenUrlCrossRefPubMed
  66. ↵
    1. Salas-Salvadó J,
    2. Díaz-López A,
    3. Ruiz-Canela M, et al.; PREDIMED-Plus investigators
    . Effect of a lifestyle intervention program with energy-restricted Mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-Plus Trial. Diabetes Care 2019;42:777–788
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Gong Q,
    2. Gregg EW,
    3. Wang J, et al
    . Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011;54:300–307
    OpenUrlCrossRefPubMedWeb of Science
  68. ↵
    1. Arnett DK,
    2. Blumenthal RS,
    3. Albert MA, et al
    . 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140:e596–e646
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes Care: 44 (Supplement 1)

In this Issue

January 2021, 44(Supplement 1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Standards of Care (PDF)
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2021
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association
Diabetes Care Jan 2021, 44 (Supplement 1) S34-S39; DOI: 10.2337/dc21-S003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association
Diabetes Care Jan 2021, 44 (Supplement 1) S34-S39; DOI: 10.2337/dc21-S003
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Lifestyle Behavior Change for Diabetes Prevention
    • Pharmacologic Interventions
    • Prevention of Vascular Disease and Mortality
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • 13. Children and Adolescents: Standards of Medical Care in Diabetes—2021
  • 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
  • 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2021
Show more Standards of Care

Similar Articles

Subjects

  • Complications-Neuropathy

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.